Scrip managing editor Jo Shorthouse talks to RedHill BioPharma, a specialty pharma company in gastrointestinal disease. Its COO, Gilead Raday, explains the company's novel antibiotic approach to Crohn's disease. This candidate, RHB-104, has met its primary and secondary endpoints in a Phase III study, and its candidate RHB-105, for H.pylori infections, is to read out Phase III data in the coming months. He also explains how RedHill BioPharma is spending the $25m it raised in the summer, and what effect this will have on the company's pipeline.
Get the latest news as it happens.